Latest Breaking News On - Wrd communications - Page 9 : comparemela.com

UCB : and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer

UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer UCB s. | May 11, 2023

Bruxelles capitaleUnited statesHelena batesLaurent schotsScott flemingAntje wittePureos bioventuresDhaval patelCharlotte hepburne scottMarie curieStrategic communicationsLife sciencesWrd communicationsCorporate communicationsAriceum therapeuticsChief scientific officer

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced

Mont saint guibertWaals gewestUnited statesNew yorkCaroline lonezDavid georgesUs securities exchangeExchange commissionBusiness developmentCompany adssCompany onWrd communicationsAdss of the companyRegulatory newsEuronext nasdaqAmerican depositary shares

Celyad Oncology Reports First Quarter 2023 Financial Results and Recent Business Highlights

Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneously Publication of results from the THINK trial, which provided proof-of-concept

United statesMont saint guibertWaals gewestNew yorkDavid georgesGeorges rawadiCaroline lonezInternational conventionBusiness developmentExchange commissionWorld oncology cell therapy congressWrd communicationsEuronext nasdaqChief executive officerLancet haematologyPrivate securities litigation reform act

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomLos angelesKyle holenMary beth woodinLavina talukdarGeralds lipshutzAmerican society of geneHead of developmentWrd communicationsModerna incExchange commissionWall streetCell therapyAnnual meetingPropionic acidemia

Moderna, Inc : Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia to be Presented at the 2023 ASGCT Annual Meeting

After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to

United statesUnited kingdomGeralds lipshutzLos angelesKyle holenMary beth woodinLavina talukdarHead of developmentAmerican society of geneWrd communicationsModerna incExchange commissionModerna inc viewCell therapyAnnual meetingPropionic acidemia